Alba María Extremera-Ortega

Alba María Extremera-Ortega

Auto-generated profile, based on publicly available information

Alba María Extremera-Ortega

Hospital General Universitario, Departamento de Alergología, Ciudad Real

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
AMAna Montoro-Ferrer
Ana Montoro-Ferrer
MMMaria del Mar Moro Moro
Maria del Mar Moro Moro
FBFernando Parra Borreguero
Fernando Parra Borreguero
AMAlvaro Moreno-Ancillo
Alvaro Moreno-Ancillo
AOAlba Extremera Ortega
Alba Extremera Ortega
MGMaría Espinosa de Los Monteros Garde
María Espinosa de Los Monteros Garde
Dupilumab has demonstrated efficacy in type 2 severe asthma in clinical trials. Real-world data, particularly from Spain and including patients with prior biologic failure, remains limited. This study evaluated the effectiveness and safety of dupilumab in a Spanish cohort with type 2 severe asthma over 12 months. Retrospective, multicenter observational study in adult and adolescent patients (≥12 years) with type 2 severe asthma treated with dupilumab for at least six months. Clinical data, including exacerbations, lung function (FEV1), Asthma Control Test (ACT), quality of life (Mini-AQLQ), systemic corticosteroid use, and biomarkers (total IgE, eosinophil count, FeNO), were collected at baseline, 6, and 12 months. The EXACTO scale was used to assess response in non-oral corticosteroid (OCS)-dependent patients at 12 months. Subgroup analyses included chronic rhinosinusitis with nasal polyps (CRSwNP) and OCS-dependent patients at baseline. A total of 156 patients were included; 54.5% had received prior biologic therapies. Significant improvements (p<0.005) from baseline to 12 months were observed in exacerbations (1.43 to 0.20 per year), FEV1 (2530.10 to 2824.59 mL), ACT (15.84 to 21.31), and Mini-AQLQ (27.24 to 74.27). Total IgE and FeNO significantly decreased whereas blood eosinophilia increased. In non-OCS-dependent patients (n=78), 56.4% were good or super-responders according to the EXACTO scale. CRSwNP patients (n=66) significantly improved in asthma and nasal symptoms. Among OCS-dependent patients (n=35), 68.6% discontinued OCS by 6 months. Comparable clinical improvements in exacerbation rates, lung function and overall response were observed in biologic-naïve and biologic-pretreated patients, consistent with similar EXACTO scores (4.92 ± 1.29 vs. 4.55 ± 1.37, respectively; p=0.166). No new safety signals were identified. This Spanish real-world study confirms sustained effectiveness and acceptable safety of dupilumab in type 2 severe asthma, including patients with prior biologic failure and comorbid CRSwNP, supporting its use in routine clinical practice.

7 June 2021 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
LMLucía Moreno-Lozano
Lucía Moreno-Lozano
OJOscar Marcelo Gonzalez Jimenez
Oscar Marcelo Gonzalez Jimenez
RGRosa María García-Rodríguez
Rosa María García-Rodríguez
AEAlba María Extremera-Ortega
Alba María Extremera-Ortega
JJJuana Bautista Joyanes-Romo
Juana Bautista Joyanes-Romo
EGElisa Gómez-Torrijos
Elisa Gómez-Torrijos
Antecedentes: Los acrilatos son materiales plásticos que se forman por la polimerización de monómeros derivados del ácido acrílico o metacrílico; tienen una amplia gama de aplicaciones y cada vez son más usados en el campo de la medicina. Casos clínicos: Presentamos dos casos clínicos de dermatitis de contacto en el entorno hospitalario: el primero se trata de una enfermera (exposición ocupacional) y el segundo, de un paciente a quien se le realizó un procedimiento diagnóstico. Conclusión: Cada año se identifican nuevas fuentes de acrilatos debido a las múltiples utilidades de estas resinas sintéticas; estos materiales se incluyen en dispositivos médicos, tanto para el diagnóstico o seguimiento (telemetría, electrodos de electroencefalógrafos) como para el tratamiento (cemento óseo) y cirugía ortopédica.